Posted by Michael Wonder on 05 Aug 2015

NICE gives green light to treatment for macular oedema in final guidance

26 February 2014 - NICE has published final guidance recommending aflibercept solution for injection (Eylea, Bayer) as an option for treating visual impairment caused by macular oedema, a condition which affects a person's ability to see detail and colour. The guidance relates to macular oedema secondary to central retinal vein occlusion (CRVO), where the vein to the retina is blocked. NICE recommends the treatment is only prescribed if the manufacturer makes it available to the NHS under terms agreed with the Department of Health as part of a patient access scheme.
For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/AfliberceptForMacularOedemaFinalGuidance.jsp

Posted by:

Michael Wonder

Posted in: